Neuronostatin-13 (human)

Name: Neuronostatin-13 (human)
Brand: MedChemExpress
SKU: HY-P1373
Rating: 4.5 (1 reviews)

製品番号: HY-P1373 純度: 99.53%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

Neuronostatin-13 (human) 構造式

CAS 番号 : 1096485-24-3

容量	価格（税別）	在庫状況	数量
1 mg	$180	在庫あり	Estimated Time of Arrival: December 31
5 mg	$450	在庫あり	Estimated Time of Arrival: December 31
10 mg	$680	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

顧客検証

•Cancer Gene Ther. 2025 Dec;32(12):1414-1427. [Abstract]

Somatostatin Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

SSTR1 SSTR2 SSTR3 SSTR5 SSTR4

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.

体外実験

Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus^[1]. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1415.68

分子式

C₆₄H₁₁₀N₂₀O₁₆

CAS 番号

1096485-24-3

Appearance

Solid

Color

White to off-white

Sequence Shortening

LRQFLQKSLAAAA-NH2

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture
Powder	-80°C	2 years
	-20°C	1 year
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

H₂O : 25 mg/mL (17.66 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7064 mL	3.5319 mL	7.0637 mL
5 mM	0.1413 mL	0.7064 mL	1.4127 mL
10 mM	0.0706 mL	0.3532 mL	0.7064 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (70.64 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

純度とドキュメンテーション

純度: 99.53%

Select Batch:

データシート (275 KB) SDS (252 KB)

COA (246 KB) LCMS (326 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Salvatori AS, et al. Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1257-63. [Content Brief]

[2]. Zhu X, et al. Neuronostatin attenuates myocardial contractile function through inhibition of sarcoplasmic reticulum Ca2+-ATPase in murine heart. Cell Physiol Biochem. 2014;33(6):1921-32. [Content Brief]

細胞実験 ^[1]	For studies examining hormone secretion from cell lines, INS 832/13 or αTC1-9 cells are plated in 96- or 24-well plates at a density of 0.25×10⁵ cells/well or 1.0×10⁵ cells/well in complete medium. The day of the experiment, cells are washed in PBS and allowed to preincubate in low- or high-glucose KRB buffer for 1 h in the presence or absence of Neuronostatin-13 human. Hormone secretion is performed using a 2-h static incubation. Supernatants are collected, and insulin or glucagon content is determined^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[2]	3-month-old adult male C57BL/6 mice are used and housed in a temperature-controlled environment (22.8±2.0°C, 45 to 50% humidity) with a 12:12h light/dark cycle with free access to food and tap water. For Neuronostatin-13 human challenge in vivo, 3-month-old adult C57BL/6 male mice are randomly divided into two groups and to receive Neuronostatin-13 human (50 μg/kg, i.p.). Cardiac function is evaluated at 3-, 6-, 12- and 18-hr after Neuronostatin-13 human treatment in the first group of animals^[2]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Salvatori AS, et al. Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1257-63. [Content Brief] [2]. Zhu X, et al. Neuronostatin attenuates myocardial contractile function through inhibition of sarcoplasmic reticulum Ca2+-ATPase in murine heart. Cell Physiol Biochem. 2014;33(6):1921-32. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.7064 mL	3.5319 mL	7.0637 mL	17.6594 mL
	5 mM	0.1413 mL	0.7064 mL	1.4127 mL	3.5319 mL
	10 mM	0.0706 mL	0.3532 mL	0.7064 mL	1.7659 mL
	15 mM	0.0471 mL	0.2355 mL	0.4709 mL	1.1773 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.